Company news
Edesa Biotech, Inc. news in 2022
Edesa Biotech, Inc.'s news releases, calls and decks from 2022, newest first.
Edesa Biotech Reports Fiscal Year 2022 Results
December 15, 2022
Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market
November 2, 2022
Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study
September 29, 2022
Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment
September 6, 2022
Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results
August 11, 2022
Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study
May 23, 2022
Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results
May 12, 2022
Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected
April 27, 2022
Edesa Biotech Appoints Strategy Expert to Board of Directors
March 28, 2022
Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering
March 23, 2022
Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
March 21, 2022
Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study
February 16, 2022
Edesa Biotech Reports Fiscal 1st Quarter 2022 Results
February 13, 2022
Edesa Biotech to Join Ontario Bioscience Panel Discussion
January 25, 2022
Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy
January 12, 2022